SELİMLİ, F. Et Al. 2025. Tempol Mitigates Methotrexate-Induced Osteotoxicity via Oxidative Stress Modulation and MAPK Pathway Inhibition. DRUG DESIGN DEVELOPMENT AND THERAPY , vol.19 , 1441-1449.

SELİMLİ, F., Reyhanioglu, M. T., HASKAN, A. C., ALTUN, M. S., Mete, S., & KAPLAN, H. M., (2025). Tempol Mitigates Methotrexate-Induced Osteotoxicity via Oxidative Stress Modulation and MAPK Pathway Inhibition. DRUG DESIGN DEVELOPMENT AND THERAPY , vol.19, 1441-1449.

SELİMLİ, FARİZ Et Al. "Tempol Mitigates Methotrexate-Induced Osteotoxicity via Oxidative Stress Modulation and MAPK Pathway Inhibition," DRUG DESIGN DEVELOPMENT AND THERAPY , vol.19, 1441-1449, 2025

SELİMLİ, FARİZ Et Al. "Tempol Mitigates Methotrexate-Induced Osteotoxicity via Oxidative Stress Modulation and MAPK Pathway Inhibition." DRUG DESIGN DEVELOPMENT AND THERAPY , vol.19, pp.1441-1449, 2025

SELİMLİ, F. Et Al. (2025) . "Tempol Mitigates Methotrexate-Induced Osteotoxicity via Oxidative Stress Modulation and MAPK Pathway Inhibition." DRUG DESIGN DEVELOPMENT AND THERAPY , vol.19, pp.1441-1449.

@article{article, author={FARİZ SELİMLİ Et Al. }, title={Tempol Mitigates Methotrexate-Induced Osteotoxicity via Oxidative Stress Modulation and MAPK Pathway Inhibition}, journal={DRUG DESIGN DEVELOPMENT AND THERAPY}, year=2025, pages={1441-1449} }